Cantor Fitzgerald Forecasts ARCT FY2025 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Arcturus Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the biotechnology company will post earnings per share of ($3.21) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.31) per share.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. The firm had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same quarter last year, the company posted ($0.61) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Monday, January 13th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $66.75.

Arcturus Therapeutics Price Performance

ARCT stock opened at $17.42 on Thursday. The firm has a 50 day simple moving average of $17.27 and a two-hundred day simple moving average of $19.74. The stock has a market cap of $471.91 million, a PE ratio of -7.85 and a beta of 2.63. Arcturus Therapeutics has a one year low of $14.30 and a one year high of $45.00.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors have recently made changes to their positions in ARCT. Sumitomo Mitsui Trust Group Inc. lifted its stake in Arcturus Therapeutics by 45.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock worth $52,819,000 after purchasing an additional 712,650 shares during the last quarter. ARK Investment Management LLC increased its holdings in shares of Arcturus Therapeutics by 6.9% in the third quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock worth $48,765,000 after buying an additional 136,074 shares during the period. Millennium Management LLC lifted its stake in shares of Arcturus Therapeutics by 250.1% in the 2nd quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock valued at $13,515,000 after acquiring an additional 396,505 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Arcturus Therapeutics by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock valued at $12,810,000 after acquiring an additional 5,789 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Arcturus Therapeutics by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock worth $4,587,000 after acquiring an additional 3,224 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.